Clinical trials: Meibomian Gland Dysfunction
Dry Eye, Meibomian Gland Dysfunction
TearCare System to Treat Dry Eye Disease
In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease.
- Trial name
- OLYMPIA (NCT03857919)
- Testing
- TearCare, LipiFlow
- Where
- 10 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Syndromes, Dry Eye
Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel®, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction.
- Conditions
- Dry Eye Syndromes, Dry Eye, Meibomian Gland Dysfunction
- Trial name
- NCT04889950
- Testing
- Tixel C, LipiFlow
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Novoxel Ltd.
Evaporative Dry Eye Disease, Meibomian Gland Dysfunction
Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease
The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction.
- Trial name
- ELM (NCT06242860)
- Testing
- ELM
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eyedetec Medical, Inc.
Dry Eye Syndromes
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to…
- Trial name
- NCT02621593
- Testing
- M22-IPL
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Lumenis Be Ltd.
Meibomian Gland Dysfunction
Contact Lens Comfort Relative to Meibomian Gland Status
This trial aims to establish a correlation between patient reported comfort while using soft contact lenses and meibomian gland dysfunction (MGD).
- Trial name
- NCT01819194
- Testing
- senofilcon A
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Dry Eye Disease
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
- Trial name
- NCT06064071
- Testing
- Nordlys SWT IPL, Meibomian Gland Expression (MGX)
- Where
- 3 sites in United States, Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Dry Eye, Sjogren's Syndrome
Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye
The study aims to test the safety of Repetitive Magnetic Stimulation (RMS) treatment for dry eye disease. Patients are asked to undergo a one-time treatment with Epitech Ocular Magnetic Stimulation Device on one eye in the first…
- Conditions
- Dry Eye, Sjogren's Syndrome, Aqueous Tear Deficiency, Meibomian Gland Dysfunction
- Trial name
- NCT03012698
- Testing
- Ocular Repetitive Magnetic Stimulation (RMS) treatment
- Where
- 3 sites in Israel
- Volunteers
- 29 people
- Sponsor
- Epitech Mag Ltd.
Meibomian Gland Dysfunction
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal…
- Trial name
- NCT03055832
- Testing
- iLux 2020 System, LipiFlow Pulsation System
- Where
- 7 sites in United States
- Volunteers
- 142 people
- Sponsor
- Tear Film Innovations, Inc.
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
The study is being conducted to evaluate the efficacy and safety of SHR8058 eye drops for patients with dry eye disease.
- Trial name
- NCT05515471
- Testing
- SHR8058 eye drops, saline eye drops.
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Palpebral Pathologies, Ocular Surface Disease
Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice
The purpose of this study is to determine the incidence and characteristics of eyelid inflammatory disorders during general ophthalmological consultations and to demonstrate association between palpebral pathologies and ocular…
- Conditions
- Palpebral Pathologies, Ocular Surface Disease, Meibomian Gland Dysfunction
- Trial name
- MEIBUM (NCT01552174)
- Where
- 2 sites in Germany, Spain
- Volunteers
- 185 people
- Sponsor
- Laboratoires Thea
Meibomian Gland Dysfunction
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
- Trial name
- NCT04391959
- Testing
- AZR-MD-001 Active, AZR-MD-001 Vehicle
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 31 people
- Sponsor
- Azura Ophthalmics
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
- Trial name
- NCT03956225
- Testing
- Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
- Where
- 15 sites in United States
- Volunteers
- 299 people
- Sponsor
- Alcon Research
Meibomian Gland Dysfunction, Dry Eye
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland…
- Trial name
- NCT02102464
- Testing
- LipiFlow treatment
- Where
- 6 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- TearScience, Inc.
Meibomian Gland Dysfunction
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.
- Trial name
- NCT04314362
- Testing
- AZR-MD-001 ointment/semi-solid drug
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- Azura Ophthalmics
Meibomian Gland Dysfunction
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical…
- Trial name
- NCT05261386
- Testing
- CBT-008
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Cloudbreak Therapeutics, LLC
Blepharitis
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
- Trial name
- NCT00656539
- Testing
- AzaSite®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Posterior Blepharitis, Meibomian Gland Dysfunction
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)
- Trial name
- NCT04469998
- Testing
- AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- AxeroVision, Inc.
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics